** Elanco Animal Health's ELAN.N shares rise 8.83% to $10.35 premarket
** Company, which makes drugs for animals, reports Q1 revenue of $1.19 billion vs est $1.17 billion - LSEG
** Raises annual forecast to be between $4.51 billion and$4.58 billion vs prior expectation of $4.45 billion to $4.51 billion
** Elanco says its outlook incorporates current estimate for tariff net impact between $16 million and $20 million to adjusted core profit
** Company's updated tariff exposure appears manageable, which was a concern heading into the print, says brokerage Leerink
** Elanco posts Q1 adjusted profit of 37 cents/shr vs est 31 cents/shr
** As of last close, stock down 22%
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。